Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of
Andrew Cheng, MD, PhD to the newly created role of Senior Vice
President, Development Operations. In this role, Dr. Cheng will be
responsible for Gilead’s biometrics, clinical operations, drug safety
and public health, project and portfolio management, and regulatory
affairs activities, reporting to Norbert Bischofberger, PhD, Executive
Vice President, Research and Development and Chief Scientific Officer.
With his promotion, Dr. Cheng will join Gilead’s Executive Committee.
Dr. Cheng joined Gilead in 1999 and most recently served as Vice
President, Clinical Research, overseeing clinical development activities
for the company’s development-stage programs in HIV/AIDS. Prior to
joining Gilead, Dr. Cheng trained in internal medicine at the University
of California, Los Angeles. He received his medical degree and PhD in
Cellular and Molecular Biology from Columbia University and
undergraduate degree from the Johns Hopkins University.
“Over the past decade, Andrew has played a key leadership role
overseeing multiple clinical programs, including pivotal studies
supporting the approval of our HIV medications and clinical program
design for our investigational HIV candidate, elvitegravir, and our
novel pharmacoenhancer, GS 9350,” commented Dr. Bischofberger. “With a
growing number of programs currently in our research and development
pipeline and the increasing complexity of our business, Andrew’s new
role will help us maintain an efficient and cost-effective approach to
development, enhancing collaboration across our four therapeutic areas
and ensuring we can advance promising candidates as quickly as possible.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs
Department at
1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
Gilead Sciences, Inc.
Patrick O'Brien, Investors, 650-522-1936
Amy
Flood, Media, 650-522-5643
